OTC:CRTHF

CARsgen Therapeutics (CRTHF) Stock Forecast, Price & News

$2.05

0.00 (0.00%)

(As of 05/12/2023)

Compare

Today's Range: $2.05
▼
$2.05
50-Day Range: $2.05
▼
$2.05
52-Week Range: $1.86
▼
$2.05

Volume: N/A
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Analyst Ratings Chart Competitors

About CARsgen Therapeutics (OTC:CRTHF) Stock

CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies in China and the U.S. The company is developing autologous CAR-T product candidates, including CT053, which targets B-cell maturation antigen that is in pivotal Phase II/III trial for the treatment of relapsed/refractory multiple myeloma; CT041, which targets Claudin 18.2, is in Phase II/III clinical trial for gastric/gastroesophageal junction cancer and Phase I for pancreatic cancer, as well as in Phase I clinical trial for gastric or pancreatic cancer; and CT011, which is in Phase I clinical trial for patients with Glypican-3 positive advanced hepatocellular carcinoma. It is also developing CT032, which targets CD19 that is in Phase I/II clinical trial for the treatment of B cell non-Hodgkin's lymphoma; CT0180, which targets Glypican-3 that is in Phase I clinical trial for patients with Glypican-3 positive advanced hepatocellular carcinoma; and CT0181, which targets Glypican-3 that is in Phase I clinical trial for patients with Glypican-3 positive hepatocellular carcinoma. In addition, the company is developing CT0590, which targets B-cell maturation antigen that is in pre-clinical stage for the treatment of relapsed/refractory multiple myeloma; CT048, which targets Claudin 18.2 that is in pre-clinical stage for the treatment of gastric/gastroesophageal junction and pancreatic cancer; KJ-C2112, an epidermal growth factor receptor/variant III of epidermal growth factor receptor, which is in pre-clinical stage for the treatment of glioblastoma; and KJC2113 that targets mesothelin, as well as KJ-C2114 that are in pre-clinical stage for the treatment of solid tumors. Further, it is developing AB011, which is in Phase I clinical trial for the treatment of gastric/pancreatic cancer. The company was founded in 2014 and is headquartered in Shanghai, China.

CRTHF Price History

30 days | 90 days | 365 days | Advanced Chart

CRTHF Stock News Headlines

March 22, 2022 | financialpost.com

UK Stocks-Factors to watch on March 22

See More Headlines

Receive CRTHF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CARsgen Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTC
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTC:CRTHF
CUSIP: N/A
CIK: N/A
Web: crestnicholson.com
Phone: 44.19.32580555
Fax: N/A
Employees: 525
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Zonghai Li M.D. (Age 48)
Ph.D., Co-Founder, CEO, CSO & Chairman
Comp: $273.92k

Dr. Huamao Wang Ph.D. (Age 46)
Co-Founder, COO & Exec. Director
Comp: $293.57k

Dr. Hua Jiang (Age 44)
Exec. Director
Comp: $316.25k

Dr. Hong Ma (Age 51)
Sr. VP of Clinical Devel.

Dr. Leigh Hsu (Age 52)
Sr. VP of Bus. Devel.

Ms. Caihua Jiang
Sr. VP of Quality

Dr. Raffaele Baffa M.D. (Age 63)
Ph.D., Chief Medical Officer

Dr. Sylvie Peltier (Age 60)
Sr. VP of Global Regulatory Affairs

Mr. Richard John Daly M.B.A. (Age 62)
Pres of CARsgen Therapeutics Corp.

Mr. Wing Yat Lui (Age 33)
Company Sec.

Key Competitors

View All Competitors

CRTHF Stock - Frequently Asked Questions

Should I buy or sell CARsgen Therapeutics stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CARsgen Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CRTHF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRTHF, but not buy additional shares or sell existing shares.
View CRTHF analyst ratings or view top-rated stocks.
How have CRTHF shares performed in 2023?: CARsgen Therapeutics' stock was trading at $2.05 at the beginning of 2023. Since then, CRTHF shares have decreased by 9.3% and is now trading at $1.86.
View the best growth stocks for 2023 here.
What is CARsgen Therapeutics' stock symbol?: CARsgen Therapeutics trades on the OTC under the ticker symbol "CRTHF."

How do I buy shares of CARsgen Therapeutics?: Shares of CRTHF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is CARsgen Therapeutics' stock price today?: One share of CRTHF stock can currently be purchased for approximately $1.86.
How many employees does CARsgen Therapeutics have?: The company employs 525 workers across the globe.
How can I contact CARsgen Therapeutics?: CARsgen Therapeutics' mailing address is Crest House, Chertsey, Surrey KT16. The official website for the company is crestnicholson.com. The company can be reached via phone at 44.19.32580555.

This page (OTC:CRTHF) was last updated on 9/25/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial